Bristol-Myers Squibb Co. and Infinity Pharmaceuticals Inc. announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) in combination with Infinity's IPI-549 in patients with advanced urothelial cancer.
ASCO and the Society for Immunotherapy of Cancer released a joint statement with twelve clinical trial reporting recommendations that address the unique efficacy, toxicity, and combination/sequencing aspects of immuno-oncology treatments.
Sandoz, a Novartis division focused on biosimilars, announced that it will not pursue its submission for biosimilar rituximab in the US at this time.
FDA has announced the availability of the MyStudies app, a mobile technology intended to foster the collection of real world evidence via patients' mobile devices.
Elsevier will integrate the National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology and utilize the NCCN Chemotherapy Order Templates as a reference into Via Oncology's Via Portal to provide clinical decision support at point of care and NCCN Guidelines concordance reporting.
Stereotactic radiosurgery offered results comparable to surgery in controlling local brain metastases, Fox Chase Cancer Center researchers have found.
A phase Ib clinical trial suggests that administering a concentrated dose of anti-CEA CAR-T cells precisely at the site of a solid tumor by means of TriSalus Life Sciences' unique Pressure-enabled Drug Delivery is safe, with encouraging clinical responses.
The Richard M. Schulze Family Foundation recently made a $6 million gift to Moffitt Cancer Center. The building formerly known as the Moffitt McKinley Outpatient Center has been renamed the Richard M. Schulze Family Foundation Outpatient Center in the foundation's honor. The naming ceremony took place Oct. 25 with Richard “Dick” Schulze in attendance.
Allen Distinguished Investigator awards, established by the philanthropist Paul G. Allen, who died Oct. 15, went to 10 investigators from several different research organizations in a variety of therapeutic areas.
